 To describe the incidence of non-serious cutaneous allergic reactions after HUMENZA or PANENZA administration in different age groups up to 21 days after the last vaccination.This study is designed to assess the safety of the approved and licensed HUMENZA adjuvanted AH1N1 pandemic influenza vaccine and PANENZA non-adjuvanted AH1N1 pandemic influenza vaccine to meet regulatory requirements for post-marketing safety monitoring. 